أفضل بودكاسات Oncology News (2024)

1
rivatization of Cancer Clinical Research Raises Concerns for Practice 13:09

3d ago13:09

13:09

“Cancer clinical research has been largely privatized,” explains Joseph Unger, PhD, MS, associate professor in the cancer prevention program at the Fred Hutchinson Cancer Center in Seattle. Dr. Unger and colleagues recently assessed patient enrollment in industry-sponsored and federally sponsored clinical trials. They found an 8:1 ratio favoring pa…

1
What 3 Big Trials Mean for Breast Cancer Practice 12:48

10d ago12:48

12:48

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756, monarchE, and NATALEE clinica…

1
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer 14:02

17d ago14:02

14:02

Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinica…

1
"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer 11:00

1M ago11:00

11:00

Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the …

1
After Practice Change in Unresectable Stage III NSCLC, Questions Remain 10:30

2M ago10:30

10:30

Data on the use of durvalumab after chemoradiotherapy transformed the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). “This is a real practice-changing observation from the PACIFIC trial,” said Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Cent…

1
What "Incredibly Dramatic" Data on Osimertinib in NSCLC Mean for Practice 9:47

2M ago9:47

9:47

Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient…

1
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates 10:08

3M ago10:08

10:08

“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with …

1
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says 11:27

3M ago11:27

11:27

Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhatia, MD, MPH, director of the Institute for Cancer Outcomes and Survivorship and the Gay and Bew White Endowed Professor in Pediatric Oncology at the University of Alabama at Birmingham. With the number …

1
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue” 12:00

3M ago12:00

12:00

Obstacles to “achieving a good, peaceful death” prevent many patients with cancer from the “dignified end” that they deserve, says Sunita Puri, MD, a palliative care physician and author. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss frustrations and …

1
FDA Approvals in Relapsed/Refractory CLL Set up "Difficult Choice" 9:59

4M ago9:59

9:59

When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have had some exciting new events," says Daniel A. Ermann, MD, a hematologist-oncologist and assistant professor at the University of Utah Huntsman Cancer Institute in Salt Lake City. The U.S. Food and Drug…

1
Oncologists Struggling With Cancer Deaths Among Millennial Patients 11:36

4M ago11:36

11:36

Oncologists are struggling with the rising cancer mortality rate among millennial patients. "I think treating people our own age is definitely a trigger for a lot of people," said Sunita Puri, MD, a palliative-care physician and author. She spoke with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai…

1
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree 12:23

4M ago12:23

12:23

Thoracic oncology was a major focus of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, says Sandip P. Patel, MD, a medical oncologist and professor of medicine at the University of California San Diego. Practice-changing data were presented in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), Dr. Patel…

1
What Were the Biggest Data at ASCO 2024 in Kidney Cancer? 11:41

4M ago11:41

11:41

The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, MD, chief of clinical trials and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center in Nashville. He discussed data from KEYNOTE-426 and several other key trials with Robert…

1
What New “Elephant in the Room” Means for Bladder Cancer Care 14:00

4M ago14:00

14:00

Enfortumab vedotin plus pembrolizumab (EV/pembro) has “become the elephant in the room” when it comes to bladder cancer care, says Jonathan E. Rosenberg, MD, chief of genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. At the 2024 American Society of Clinical Oncology Annual Meeting, he discussed recent key ad…

1
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice 12:08

4M ago12:08

12:08

Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice Our host, Robert A. Figlin, MD, FACP, welcomes Melissa L. Johnson, MD, as a guest

1
"We're Past the Inflection Point," as "Massive Change" Hits Breast Cancer Care 13:54

4M ago13:54

13:54

From ASCO 2024. When it comes to the use of antibody-drug conjugates (ADCs) in breast cancer care, "we're past the inflection point," says Hope S. Rugo, MD, a breast cancer oncologist and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.…

1
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA"? 13:06

4M ago13:06

13:06

From ASCO 2024 The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City and associate…

1
"Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More 12:32

5M ago12:32

12:32

From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas. "Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.

1
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected" 10:29

5M ago10:29

10:29

From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center. Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"

1
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says 25:13

5M ago25:13

25:13

From ASCO 2024 New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says. Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University

1
Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That" 10:46

5M ago10:46

10:46

From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center. Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"

1
Oncologist Shortage “Has Gotten to the Crisis Level” 10:02

6M ago10:02

10:02

Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology a…

1
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use 9:20

7M ago9:20

9:20

The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spiel…

1
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care 11:01

7M ago11:01

11:01

Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at the University of Colorado in Aurora. Dr. Bunn discuss…

1
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer 11:16

8M ago11:16

11:16

The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data from the recent EMBARK trial have changed practice for…

1
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming” 11:26

8M ago11:26

11:26

The U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work …

1
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care 10:48

8M ago10:48

10:48

Recent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. From the recent approval of enfortumab vedotin plus pemb…

1
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression 11:57

9M ago11:57

11:57

Recent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles H. Dewey Professor at the University of Rochester in New York, highlights which recent dev…

1
Controversies, Difficult Questions Arise in NSCLC Amid New Data 11:22

9M ago11:22

11:22

Recent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad of questions. These include controversial topics and difficult decisions, like when to incorporate CTLA-4 inhibition and what patients can expect from immuno-oncology monotherapy in the metastatic set…

1
What FDA Approval of Belzutifan Means for Kidney Cancer Care 10:08

9M ago10:08

10:08

Belzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcinoma. How should this drug best be incorporated into practice? Eric Jonasch, MD, professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Hous…

1
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer 12:04

9M ago12:04

12:04

CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. …

1
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023? 10:32

11M ago10:32

10:32

From compelling data presented at the San Antonio Breast Cancer Symposium to the recent U.S. Food and Drug Administration approval of capivasertib, 2023 saw numerous key advances in breast cancer care. Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor at Harvard Medical …

1
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances 11:30

11M ago11:30

11:30

From the use of prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) to advancements in targeted treatments, prostate cancer care is quickly evolving. Edwin M. Posadas, MD, director of the Experimental Therapeutics Program and director of the Center for Urologic Oncology Research Excellence at Cedars-Sinai in Los Angeles, sp…

1
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit 11:56

11M ago11:56

11:56

Results of the recent EMBARK study show that both enzalutamide plus leuprolide and enzalutamide monotherapy significantly improved metastasis-free survival compared with leuprolide alone in patients with prostate cancer who have high-risk biochemical recurrence. Lead author Stephen Freedland, MD, associate director for education and training and di…

1
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023 11:47

12M ago11:47

11:47

Studies involving high-risk, early-stage ER-positive breast cancer are among the most eagerly anticipated at this year’s San Antonio Breast Cancer Symposium (SABCS), to be held Dec. 5-9. Virginia Kaklamani, MD, professor of medicine in the division of hematology and medical oncology at the University of Texas Health Sciences Center San Antonio and …

1
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned 13:15

12M ago13:15

13:15

Last month, a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) determined that progression-free survival (PFS) could not be reliably interpreted in a confirmatory clinical trial for sotorasib (Lumakras) used to treat KRAS G12C–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Ravi A. Madan, …

1
First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy 9:15

1y ago9:15

9:15

How should results of the FLAURA2 clinical trial be applied in practice? The study examined the use of osimertinib plus chemotherapy in the first-line treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared with osimertinib alone and found that progression-free survival was significantly improved with the combination treatmen…

1
What Recent “Outstanding Results” in MCL Mean for Practice 11:13

1y ago11:13

11:13

“Therapies are improving dramatically” in mantle cell lymphoma (MCL), according to Michael Wang, MD, professor in the department of lymphoma/myeloma, division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston. Dr. Wang presented updates on major advances in MCL at the recent Society of Hematologic Oncology (SOHO) an…

1
The Quest to Cure CLL: “Remarkable” Results With New Strategy 16:00

1y ago16:00

16:00

Recent advances have provided new options for when and how best to treat patients with chronic lymphocytic leukemia (CLL). Trials of combination strategies have shown promise in providing patients the potential for unmaintained remissions. Marco Ruella, MD, an assistant professor of medicine in hematology-oncology at the Perlman School of Medicine …

1
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice? 14:18

1y ago14:18

14:18

The World Conference on Lung Cancer (World Lung) will be held in Singapore, September 9–12. The current president of International Association for the Study of Lung Cancer (IASLC), Heather A. Wakelee, MD, division chief of medical oncology at the Stanford Cancer Institute in California, shares which presentations and findings she is most looking fo…

1
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations 15:07

1+ y ago15:07

15:07

Updates to the American Society for Clinical Oncology’s (ASCO’s) living guidelines for therapy in patients with stage IV non-small cell lung cancer (NSCLC) with driver alterations were recently released. Dwight H. Owen, MD, MS, from The Ohio State University Comprehensive Cancer Center – James, examines the new recommendations that he and his team …

1
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists 13:24

1+ y ago13:24

13:24

In early July, beloved surgeon and breast cancer advocate Susan Love, MD, MBA, died at age 75 years, after a recurrence of leukemia. Dr. Love’s legacy extends beyond the lives of her patients and into the approaches and attitudes of her fellow physicians. Stephanie Graff, MD, medical advisor to the Dr. Susan Love Foundation for Breast Cancer Resear…

1
Will HER3 Targeting Change Breast Cancer Care? 12:43

1+ y ago12:43

12:43

HER2 inhibitors dramatically changed care for many breast cancers; however, less is known about HER3, which acts in concert with HER2. Does HER3 have the same potential to reshape treatment strategies? Erika Hamilton, MD, director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville, talks with Bob Figlin…

1
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now 13:36

1+ y ago13:36

13:36

Although findings have suggested that adjuvant osimertinib is beneficial in early-stage non-smallcell lung cancer (NSCLC), some concerns have persisted. Balazs Halmos, MD, MS, associate director of clinical science, and director of both thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center in New York, says that “all t…

1
“Don't Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer 13:21

1+ y ago13:21

13:21

How should community oncologists best approach ESR1 mutations in breast cancer, given the latest findings? Recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and elsewhere have shed light on issues related to ESR1 testing and treatment selection. Bob Figlin, MD, the Steven Spielberg Family Chair in hematol…

1
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next? 11:57

1+ y ago11:57

11:57

Recent results demonstrated that mRNA vaccination improved recurrence-free survival among patients with melanoma. This has led to questions about what’s next for this promising intervention. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los Angeles, welcomes Jeffrey Weber, MD, PhD, deputy directo…

1
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice 11:44

1+ y ago11:44

11:44

Within the last few years, an “explosion of data” regarding adjuvant and neoadjuvant treatment for resectable lung cancer has contained “major wins” for patient care. Although exciting, the rapid advancement has led to questions about when chemotherapy and chemoimmunotherapy should be adopted or avoided. Bob Figlin, MD, the Steven Spielberg Family …

1
“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?” 14:37

1+ y ago14:37

14:37

As treatment options increase for patients with CLL, so do questions about which interventions, if any, are right for which patients and when. Bob Figlin, MD, and Nicole Lamanna, MD, discuss key considerations, ranging from cardiac toxicity to why Dr. Lamanna “won't just treat for a symptom.”

1
Pragmatica-Lung Tests a Treatment and a New Approach to Trials 9:51

1+ y ago9:51

9:51

The newly opened Pragmatica-Lung trial compares ramucirumab plus pembrolizumab versus usual care for treatment of stage IV or recurrent non-small cell lung cancer. The trial is designed to ease enrollment requirements and data collection needs, focusing on the key endpoint of overall survival. Listen as study lead Karen Reckamp, MD, professor and d…

1
The Best First Step in Metastatic NSCLC Care 9:13

1+ y ago9:13

9:13

With more than 10 known driver mutations in non-small cell lung cancer (NSCLC), testing is ever more critical, says Heather Wakelee, MD, division chief of medical oncology at Stanford University and president of the International Association for the Study of Lung Cancer. Listen as she and Peer-Spectives host Bob Figlin, MD, the Steven Spielberg Fam…

المدونة الصوتية تستحق الاستماع

Oncology News بودكاست

المدونة الصوتية تستحق الاستماع

دليل مرجعي سريع